Supplement shows promise for thinning hair in women over 50
NCT ID NCT07300228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a daily supplement called Olistic Next Women in 39 women aged 50-65 with early female pattern hair loss. Over 6 months, researchers measured changes in hair density and shedding. The goal was to see if the supplement could help control hair thinning without changing other routines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
39 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 50-65. * Volunteers with initial FPHL. (Images will be sent to a dermatologist for assessment). * Commitment not to use systemic, topical, or oral products with an effect similar to that of the product to be evaluated throughout the study period. * Do not change the daily routine regarding the use of cosmetic products and eating habits. * Commitment to comply with all protocol requirements specified in the subject information sheet. * Availability to comply with all study visits. Exclusion Criteria: * Women who have undergone dermatological treatment for hair loss (PRPs, mesotherapy, etc.) or hair transplant. * Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate severe seborrheic dermatitis, eczema, cancer, etc. * Women who present alopecia because of a medical illness (hypothyroidism, anemia, lupus, etc.). * Relevant cutaneous marks in the experimental areas, which could interfere with the measurements (scars, sunburns, etc.). * In-use relevant pharmacological or hormonal treatment (eg. valproic acid, carbamazepine, phenytoin). * Women with thyroid alteration (hyper- or hypothyroidism) * Women who have previously participated in similar studies or who have used anti-hair loss products in the last 3 months. * Women who are being treated with anticoagulants, antifungals, anxiolytics, amphetamines, retinoids, iron, antithyroid, anticonvulsants, beta blockers and/or ACE inhibitors, minoxidil, finasteride, etc. * Women who started hormonal treatment (oral or topical contraceptives) in the 6 months prior to the start of the study. * Women who started taking any drug chronically less than 6 months before the start of the study (they should have a stable situation with the medication over 6 months). * Modification of the usual diet: low-calorie diet, Atkins diet, etc. * Evidence of systemic diseases (e.g. cardiac disease, psychiatric disease, etc.) or gastrointestinal diseases. * Serious conditions or illnesses that, in the opinion of the researcher, may be aggravated by participation in the study or that put the development of the study at risk. * Planned hairstyle changes throughout the study * Presence of skin diseases or melanomas. * Forecast of change of routine or relevant way of life, during the period of study. * Other exclusion criteria to be added by the investigator. * Allergy or reactivity to some of the components of the product, or a product with similar category than tested one. * Women who have gone dermatological treatment, that they have introduced minoxidil (oral or topical) at least 6 months prior, and antiandrogens (e.g. finasteride) at least 12 months before the start of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early female pattern hair loss (FPHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bionos Biotech Clínica
Valencia, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.